流感诊断市场规模、份额、成长分析、按产品、按测试、按最终用户、按地区 - 行业预测，2024-2031 年

2022年全球流感诊断市场规模估值为13亿美元，从2023年的14亿美元成长到2031年的21亿美元，预计在预测期内（2024-2031年）复合年增长率为4.9%。

医疗保健支出的增加和有效治疗方法的进步正在导致世界中位数年龄的上升。世界卫生组织、疾病预防控制中心和欧洲疾病预防和控制中心等监管机构努力追踪发病率和盛行率资料，以系统化应对健康挑战。全球流感计画 (GIP) 等联合倡议旨在加强管理流感及相关流行病的技术援助和策略指南。儘管做出了这些努力，COVID-19 大流行仍严重影响了流感诊断市场，导致生产设施暂时关闭和供应链中断。此外，COVID-19 和流感症状的相似性需要同时进行检测，在这些挑战中推动了对流感诊断的需求，并最终推动了我们正在推广的这一细分市场的成长。

目录

介绍

• 研究目的
• 调查范围
• 定义

调查方法

• 资讯采购
• 二手资料和主要资料方法
• 市场规模预测
• 市场假设与限制

执行摘要

• 全球市场展望
• 供需趋势分析
• 按细分市场的机会分析

市场动态及展望

• 市场概况
• 市场规模
• 市场动态
  • 驱动因素和机会
  • 限制因素和挑战
• 波特分析及影响
  • 竞争公司之间的敌对关係
  • 替代品的威胁
  • 买方议价能力
  • 新进入者的威胁
  • 供应商的议价能力

主要市场考察

• 关键成功因素
• 竞争程度
• 主要投资机会
• 市场生态系统
• 市场吸引力指数（2023）
• PESTEL分析
• 总体经济指标
• 价值链分析
• 价格分析
• 技术进步
• 监管环境
• 案例研究
• 专利分析

流感诊断市场规模：依产品及复合年增长率（2024-2031）

• 市场概况
• 检测套组和试剂
• 装置
• 其他的

流感诊断市场规模：按测试和复合年增长率（2024-2031）

• 市场概况
• 分子诊断测试
  • 聚合酵素链锁反应
  • 恒温核酸增幅试验
  • 检查
• 基于转录扩增的测试
• 恒温环型核酸扩增的测试
• 基于核酸序列的扩增测试
• 常规诊断测试
• 流感快速诊断检测
• 病毒培养测试
• 直接萤光抗体测试
• 血清学检测

流感诊断市场规模：依最终用户和复合年增长率（2024-2031）

• 市场概况
• 诊断实验室
• 医院和诊所
• 其他的

流感诊断市场规模与复合年增长率（2024-2031）

• 北美洲
  • 美国
  • 加拿大
• 欧洲
  • 英国
  • 德国
  • 西班牙
  • 法国
  • 义大利
  • 其他欧洲国家地区
• 亚太地区
  • 中国
  • 印度
  • 日本
  • 韩国
  • 其他亚太地区
• 拉丁美洲
  • 巴西
  • 其他拉丁美洲地区
• 中东/非洲
  • 海湾合作委员会国家
  • 南非
  • 其他中东/非洲

竞争资讯

• 前5名企业对比
• 主要企业市场定位（2023年）
• 主要市场参与者所采取的策略
• 近期市场趋势
• 公司市场占有率分析（2023）
• 主要企业简介
  • 公司简介
  • 产品系列分析
  • 按细分市场分類的份额分析
  • 收益与前一年同期比较（2021-2023）

主要企业简介

• Thermo Fisher Scientific（US）
• Becton, Dickinson and Company（US）
• F. Hoffmann-La Roche AG（Switzerland）
• Hologic, Inc.（US）
• Abbott Laboratories, Inc.（US）
• DiaSorin（Italy）
• QIAGEN NV（Netherlands）
• Fujirebio Diagnostics, Inc.（Japan）
• Meridian Bioscience, Inc.（US）
• Luminex Corporation（US）
• Seegene Inc.（South Korea）
• Bio-Rad Laboratories, Inc.（US）
• Alere Inc.（US）
• GenMark Diagnostics, Inc.（US）
• Roche Diagnostics（Switzerland）
• BioMerieux SA（France）
• Cepheid（US）
• SD Biosensor（South Korea）
• Acon Laboratories, Inc.（US）
• Inverness Medical Innovations, Inc.（US）

结论和建议

Global Influenza Diagnostics Market size was valued at USD 1.3 billion in 2022 and is poised to grow from USD 1.4 billion in 2023 to USD 2.1 billion by 2031, growing at a CAGR of 4.9% during the forecast period (2024-2031).

Rising healthcare expenditures and effective treatment advancements are contributing to a global increase in median age. Regulatory organizations such as WHO, CDC, and the European Centre for Disease Prevention and Control are diligently tracking incidence and prevalence data to systematically address health challenges. Collaborative initiatives like the Global Influenza Program (GIP) aim to enhance technical support and strategic guidance in managing influenza and related pandemics. Despite these efforts, the COVID-19 pandemic has significantly impacted the influenza diagnostics market, leading to temporary closures of manufacturing facilities and disruptions in supply chains. Furthermore, the similarities between COVID-19 and influenza symptoms necessitate concurrent testing, driving the demand for influenza diagnostics amidst these challenges, ultimately fostering growth in this market sector during the forecast period.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Influenza Diagnostics market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Influenza Diagnostics Market Segmental Analysis

Global Influenza Diagnostics Market is segmented by Product, Test, End User and Region. Based on Product, the market is segmented into Test kit and Reagents, Instruments, Other Products. Based on Test, the market is segmented into Molecular Diagnostic Test (Polymerase Chain Reaction, Isothermal Nucleic Acid Amplification, Tests), Transcription Mediated Amplification Based Assay, Loop Mediated Isothermal Amplification Based Assay, Nucleic Acid Sequence based Amplification Tests, Traditional Diagnostics Tests (Rapid Influenza Diagnostic Test, Viral Culture Test, Direct Fluorescent Antibody Test, Serological Tests). Based on End User, the market is segmented into Diagnostic Laboratories, Hospitals and Clinics, Others. Based on Region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Influenza Diagnostics Market

A key driver in the global Influenza Diagnostics market is the increased emphasis on research and development in this area. The escalating global incidence of influenza has intensified efforts to create accurate and rapid diagnostic methods for identifying influenza viruses. This focus on enhancing diagnostic capabilities is expected to significantly propel market growth. Furthermore, government initiatives aimed at combating influenza outbreaks, along with advancements in technology, are enhancing diagnostic efficacy. Additionally, the growing prevalence of related health issues, such as cardiovascular diseases and diabetes, will also contribute to the upward momentum of the Influenza Diagnostics market.

Restraints in the Global Influenza Diagnostics Market

The Global Influenza Diagnostics market faces several restraints, particularly the shortage of skilled technicians, which significantly hampers its growth potential. The scarcity of qualified professionals, compounded by an unstable regulatory environment regarding the approval of new diagnostic tests, poses a considerable challenge. Additionally, developing economies often struggle with inadequate healthcare infrastructure, further complicating the situation. As a result, these factors collectively hinder the market's expansion, making it more difficult to implement and utilize advanced diagnostic technologies effectively in the fight against influenza. Addressing these issues is crucial for fostering growth and improving diagnostic capabilities worldwide.

Market Trends of the Global Influenza Diagnostics Market

The global influenza diagnostics market is poised for substantial growth, driven by a notable rise in reported influenza cases worldwide. With the Centers for Disease Control and Prevention (CDC) estimating annual influenza-related fatalities in the U.S. between 12,000 and 79,000, the urgency for effective diagnostic solutions becomes ever more critical. Furthermore, heightened awareness surrounding the significance of early detection and proactive disease management is propelling demand for advanced testing technologies. As healthcare providers and patients prioritize timely intervention to mitigate influenza outbreaks, the market is expected to expand significantly during the forecast period, reflecting both public health imperatives and technological advancements in diagnostics.

Table of Contents

Introduction

• Objectives of the Study
• Scope of the Report
• Definitions

Research Methodology

• Information Procurement
• Secondary & Primary Data Methods
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Global Market Outlook
• Supply & Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Overview
• Market Size
• Market Dynamics
  • Driver & Opportunities
  • Restraints & Challenges
• Porters Analysis & Impact
  • Competitive rivalry
  • Threat of substitute
  • Bargaining power of buyers
  • Threat of new entrants
  • Bargaining power of suppliers

Key Market Insights

• Key Success Factors
• Degree of Competition
• Top Investment Pockets
• Market Ecosystem
• Market Attractiveness Index, 2023
• PESTEL Analysis
• Macro-Economic Indicators
• Value Chain Analysis
• Pricing Analysis
• Technological Advancement
• Regulatory Landscape
• Case Studies
• Patent Analysis

Influenza Diagnostics Market Size by Product & CAGR (2024-2031)

• Market Overview
• Test kit and Reagents
• Instruments
• Others

Influenza Diagnostics Market Size by Test & CAGR (2024-2031)

• Market Overview
• Molecular Diagnostic Test
  • Polymerase Chain Reaction
  • Isothermal Nucleic Acid Amplification
  • Tests
• Transcription Mediated Amplification Based Assay
• Loop Mediated Isothermal Amplification Based Assay
• Nucleic Acid Sequence based Amplification Tests
• Traditional Diagnostics Tests
• Rapid Influenza Diagnostic Test
• Viral Culture Test
• Direct Fluorescent Antibody Test
• Serological Test

Influenza Diagnostics Market Size by End User & CAGR (2024-2031)

• Market Overview
• Diagnostic Laboratories
• Hospitals and Clinics
• Others

Influenza Diagnostics Market Size & CAGR (2024-2031)

• North America, (Product, Test, End User)
  • US
  • Canada
• Europe, (Product, Test, End User)
  • UK
  • Germany
  • Spain
  • France
  • Italy
  • Rest of Europe
• Asia-Pacific, (Product, Test, End User)
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia Pacific
• Latin America, (Product, Test, End User)
  • Brazil
  • Rest of Latin America
• Middle East & Africa (Product, Test, End User)
  • GCC Countries
  • South Africa
  • Rest of Middle East & Africa

Competitive Intelligence

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Developments in the Market
• Company Market Share Analysis, 2023
• Company Profiles of All Key Players
  • Company Details
  • Product Portfolio Analysis
  • Company's Segmental Share Analysis
  • Revenue Y-O-Y Comparison (2021-2023)

Key Company Profiles

• Thermo Fisher Scientific (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Becton, Dickinson and Company (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• F. Hoffmann-La Roche AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hologic, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Abbott Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• DiaSorin (Italy)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• QIAGEN N.V. (Netherlands)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Fujirebio Diagnostics, Inc. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Meridian Bioscience, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Luminex Corporation (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Seegene Inc. (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bio-Rad Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Alere Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GenMark Diagnostics, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Roche Diagnostics (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• BioMerieux SA (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cepheid (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• SD Biosensor (South Korea)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Acon Laboratories, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Inverness Medical Innovations, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments

Conclusion & Recommendation